AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 DEC 5 - (NewsRx.com & NewsRx.net) -- Antex Biologics, Inc. (ANX) has completed laboratory analyses of its Phase 1B clinical trial of Helivax, the Company's oral vaccine intended to prevent and treat gastrointestinal infections and disease caused by Helicobacter pylori.
The primary objective of this second human trial was to evaluate the effect of mucosal adjuvant doses with several different vaccine formulations. As reported earlier, all formulations and dosages were found to be safe and did not cause any adverse clinical events, and the vaccine stimulated serum, mucosal and salivary antibodies against H. pylori.
The laboratory analysis of the cellular immune response and fecal antibody production has been completed. As anticipated based on the earlier reported results, the vaccinated volunteers were positive for immune cell proliferation, cytokine production, and secretory IgA antibodies. These efficacy results provide the basis for proceeding to a Phase II clinical trial, which will be conducted in early 2002.
"The results of this Phase IB trial ...
Source: HighBeam Research, Vaccine Progresses to Phase II Human Trails.(Brief Article)